Key result
Subcutaneous LMWH after primary PCI for STEMI reduced the occurrence of left ventricular thrombus compared to no anticoagulation.
Why the study?
The efficacy and safety of postprocedure anticoagulation following PPCI for STEMI remain debated due to limited data and unclear guidelines.
Does subcutaneous LMWH after primary percutaneous coronary intervention reduce LV thrombus and ischemic events in STEMI patients?
RCT (n=97)
randomly assigned
No
Does subcutaneous LMWH after primary percutaneous coronary intervention reduce LV thrombus and ischemic events in STEMI patients?
Prolonged postprocedural anticoagulation with LMWH after primary PCI for STEMI significantly reduces the risk of LV thrombus without increasing bleeding risks.
Answers are grounded in this paper and cite their sources.
Supports LMWH after primary PCI in STEMI; extends RCT evidence for postprocedural anticoagulation to prevent LV thrombus.
Background:ST-elevation myocardial infarction (STEMI) results from the occlusion of coronary arteries, with plaque rupture being a common cause. Anticoagulant therapy is crucial during primary percutaneous coronary intervention (PPCI) for STEMI, yet the efficacy and safety of postprocedure anticoagulation (PPAC) remain debated due to limited data and unclear guidelines. Objective: This study aimed to evaluate the rationale of anticoagulation prolongation versus no anticoagulation after pPCI for STEMI. Subjects and Methods: This randomized controlled clinical study was performed at the Cardiology Department of the Nasser Institute for Research and Treatment. Ninety-seven STEMI patients undergoing PPCI were randomly assigned to two groups: 49 patients received no subcutaneous low molecular weight heparin (LMWH) after PPCI (Group 1), and 48 patients received subcutaneous LMWH (Group 2). The parameters assessed included demographic data, clinical examination findings, laboratory investigations, ECG, echocardiography, and PCI findings. Results: This study found no significant differences in baseline characteristics, vital signs, clinical examination outcomes, and most procedural characteristics between the groups. However, a significant difference was observed in the occurrence of left ventricular (LV) thrombus, with 8.2% of group 1 exhibiting LV thrombus compared to none in group 2 (P = 0.043). There were no significant differences in follow-up outcomes, including acute heart failure, bleeding, hemodynamically unstable arrhythmia, ischemic thrombus, stroke, myocardial infarction, and death. Conclusions: Prolonged postprocedural anticoagulation after PPCI for STEMI significantly reduced in-hospital morbidity and the risk of LV thrombus without increasing bleeding risks. This suggests a superior efficacy of post-PPCI anticoagulation in mitigating ischemic events.
No takes yet. Share an insight, caveat, or question.
A 2024 study conducted an RCT in ST-segment elevation myocardial infarction (STEMI) (n=97). Subcutaneous low molecular weight heparin (LMWH) vs. No subcutaneous LMWH was evaluated on Occurrence of left ventricular (LV) thrombus (p=0.043). Subcutaneous LMWH after primary PCI for STEMI reduced the occurrence of left ventricular thrombus compared to no anticoagulation.
Synapse has enriched 10 related papers. Consider them for comparative context: